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Macrophage migration inhibitory factor downregulation: a
novel mechanism of resistance to anti-angiogenic therapy
BA Castro1, P Flanigan1, A Jahangiri1, D Hoffman, W Chen, R Kuang, M De Lay, G Yagnik, JR Wagner, S Mascharak, M Sidorov,
S Shrivastav, G Kohanbash, H Okada and MK Aghi
Anti-angiogenic therapies for cancer such as VEGF neutralizing antibody bevacizumab have limited durability. While mechanisms of
resistance remain undefined, it is likely that acquired resistance to anti-angiogenic therapy will involve alterations of the tumor
microenvironment. We confirmed increased tumor-associated macrophages in bevacizumab-resistant glioblastoma patient
specimens and two novel glioblastoma xenograft models of bevacizumab resistance. Microarray analysis suggested downregulated
macrophage migration inhibitory factor (MIF) to be the most pertinent mediator of increased macrophages. Bevacizumab-resistant
patient glioblastomas and both novel xenograft models of resistance had less MIF than bevacizumab-naive tumors, and harbored
more M2/protumoral macrophages that specifically localized to the tumor edge. Xenografts expressing MIF-shRNA grew more
rapidly with greater angiogenesis and had macrophages localizing to the tumor edge which were more prevalent and proliferative,
and displayed M2 polarization, whereas bevacizumab-resistant xenografts transduced to upregulate MIF exhibited the opposite
changes. Bone marrow-derived macrophage were polarized to an M2 phenotype in the presence of condition-media derived from
bevacizumab-resistant xenograft-derived cells, while recombinant MIF drove M1 polarization. Media from macrophages exposed to
bevacizumab-resistant tumor cell conditioned media increased glioma cell proliferation compared with media from macrophages
exposed to bevacizumab-responsive tumor cell media, suggesting that macrophage polarization in bevacizumab-resistant
xenografts is the source of their aggressive biology and results from a secreted factor. Two mechanisms of bevacizumab-induced
MIF reduction were identified: (1) bevacizumab bound MIF and blocked MIF-induced M1 polarization of macrophages; and (2) VEGF
increased glioma MIF production in a VEGFR2-dependent manner, suggesting that bevacizumab-induced VEGF depletion would
downregulate MIF. Site-directed biopsies revealed enriched MIF and VEGF at the enhancing edge in bevacizumab-naive patients.
This MIF enrichment was lost in bevacizumab-resistant glioblastomas, driving a tumor edge M1-to-M2 transition. Thus,
bevacizumab resistance is driven by reduced MIF at the tumor edge causing proliferative expansion of M2 macrophages, which in
turn promotes tumor growth.
Oncogene (2017) 36, 3749–3759; doi:10.1038/onc.2017.1; published online 20 February 2017
INTRODUCTION
Anti-angiogenic therapy holds promise for treating malignancies
such as glioblastoma, a devastating brain cancer whose median
survival of under two years from diagnosis1 creates an urgent
need for effective treatments. Unfortunately, while initial
responses to anti-angiogenic therapy are often significant, these
agents have limited durations of response.2 Half of glioblastomas
treated with bevacizumab, a neutralizing antibody targeting
vascular endothelial growth factor (VEGF), develop acquired
resistance after initial response.3 Acquired resistance to anti-
angiogenic therapy confers a poor prognosis,1,4 making it a
significant problem preventing anti-angiogenic therapies from
fulfilling their therapeutic promise.
Increased tumor-associated macrophages (TAMs) have been
described in preclinical5 and clinical6 specimens of glioblastomas
whose tumors progress during bevacizumab treatment and
correlate with a poor prognosis in these patients7 but the links
between VEGF blockade, TAM recruitment and resistance have yet
to be established. We sought to identify a comprehensive
mechanism defining the role of macrophages in bevacizumab
resistance that accounts for tumor-secreted cytokines regulating
TAMs, spatial heterogeneity in TAM localization and the evolution
of our understanding that TAMs fall into two subtypes: M1
classically-activated macrophages with pro-inflammatory antitu-
moral function and M2 alternatively-activated macrophages,
which promote tumor growth and invasion.8–10
RESULTS
Increased myeloid macrophages in bevacizumab-resistant
glioblastomas
Immunostaining revealed that bevacizumab-resistant glioblasto-
mas had more IBA1+ cells, a marker of myeloid-derived macro-
phages than microglia,11 than their paired pre-treatment
bevacizumab-naive glioblastomas (P= 0.02), while no such
increase occurred when glioblastomas recurred without bevaci-
zumab treatment (P= 0.8) (n= 8/group) (Figure 1a). To confirm
that these IBA1+ cells expanding in resistant glioblastomas were
marrow-derived macrophages recruited through the disrupted
blood–brain barrier of glioblastoma rather than native microglia,
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we performed absolute qPCR for microglia marker CX3CR1 and
myeloid macrophage marker CCR212,13 on CD11b+ cells isolated
from site-directed biopsies of the central core, enhancing edge
and infiltrated white matter of patient glioblastomas as illustra-
ted in Supplementary Figure S1. The ratio of CCR2 to CX3CR1
expression was greater in all sites of bevacizumab-resistant (n= 3;
one after monotherapy and two after combination therapy)
versus bevacizumab-naive (n= 5) glioblastomas (P= 0.006–0.02)
(Figure 1b), consistent with these increased IBA1+ cells in
bevacizumab-resistant glioblastoma being marrow-derived.
We then corroborated these findings in two different intracra-
nial xenograft models of bevacizumab resistance established by
our group. First, we analyzed CD11b+ cells in patient-derived
intracranial bevacizumab-sensitive SF7300 and bevacizumab-
resistant SF7796 xenografts, which were derived from samples
taken at the enhancing edge of patient tumors and whose
bevacizumab responsiveness mirrors that of the patient glioblas-
toma they derive from.14 We found that bevacizumab increased
CD11b+ cells significantly in both bevacizumab sensitive SF7300
(P= 0.01) and bevacizumab-resistant SF7796 (P= 0.002) xenografts
Figure 1. Increased M2 macrophages at the tumor edge associated with bevacizumab-resistant glioblastoma. (a) Human glioblastomas
(n= 8/group) exhibited increased IBA1+ macrophages upon becoming bevacizumab-resistant compared to paired pre-treatment
bevacizumab-naive specimens (P= 0.02), while no such increase occurred in bevacizumab-naive glioblastomas after recurrence compared
with before (P= 0.8) Y-axis represents percent of the high-powered field that was immunopositive as derived by ImageJ software. (b) Absolute
qPCR for microglia marker CX3CR1 and myeloid macrophage marker CCR2 on CD11b+ cells isolated from site-directed biopsies of the central
core, enhancing edge, and infiltrated white matter of patient glioblastomas revealed that the ratio of CCR2:CX3CR1 expression increased
robustly in all sites of bevacizumab-resistant (n= 3) versus bevacizumab-naive (n= 5) glioblastomas (P= 0.006 central core; P= 0.01 enhancing
edge; P= 0.02 infiltrated white matter) (c) U87-BevS and U87-BevR intracranial xenografts exhibited increased CD11b+ macrophages (red) upon
treatment with bevacizumab compared with treatment with IgG (P= 0.01). These macrophages were recruited to the tumor (green) edge
(n= 5/group). (d) THP-1 human monocytes exhibited decreased chemotaxis in response to U87-BevR conditioned media (CM) compared with
U87-BevS CM (Po0.0001) (n= 4/group), whereas (e) murine bone marrow derived macrophages had greater cell numbers when cultured in
U87-BevR conditioned media for 48 h compared with U87-BevS conditioned media (P= 0.04), with both U87-BevR (Po0.001) and U87-BevS
(P= 0.04) conditioned media increasing macrophage numbers (n= 8/group). (f) qPCR of FACS-sorted CD11b+ TAMs isolated from intracranial
U87-BevR and U87-BevS xenograft (n= 5/group) revealed increased M2 macrophages in U87-BevR intracranial xenografts relative to U87-BevS
intracranial xenografts, independent of treatment (Po0.0001), as revealed by M2/M1 polarization ratios determined by multiplying the qPCR
fold increases in three different M2 primers divided by the qPCR fold increases in three different M1 primers normalized to results for
U87-BevS xenografts treated with IgG.
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(Supplementary Figure S2), but the increase in CD11b+ cells was
significantly larger in bevacizumab-resistant SF7796 than
bevacizumab-sensitive SF7300 xenografts (111 vs 44%, P= 0.01).
Second, we analyzed TAMs in intracranial xenografts derived from
U87-BevR and U87-BevS, isogeneic cell line-derived bevacizumab-
resistant and sensitive xenograft models, respectively, whose
establishment we described.14,15 Immunostaining revealed
increased CD11b+ cells in bevacizumab-treated sensitive and
resistant xenografts relative to those treated with IgG control
antibody (Figure 1c; P= 0.01). Interestingly, the CD11b+ cells
associated with bevacizumab treatment localized to the tumor
edge (Figure 1c). Furthermore, the increased CD11b+ cells seen in
bevacizumab-treated sensitive and resistant xenografts proved to
be a mixture of marrow-derived macrophages recruited from the
circulation and native microglia based on absolute qPCR of
isolated tumoral CD11b+ cells for microglia marker CX3CR1 and
myeloid macrophage marker CCR2 (Supplementary Figure
S3a).12,13 Bevacizumab increased expression of marrow-derived
TAM marker CCR2 relative to microglial marker CX3CR1 in U87-
BevS xenografts (P= 0.01); however, IgG-treated U87-BevR xeno-
grafts had a greater CCR2:CX3CR1 ratio and bevacizumab did not
increase this ratio (P= 0.6) (Supplementary Figure S3a). Further-
more, bevacizumab lowered expression of microglia marker
TMEM119 16 in the CD11b+ cells in U87-BevS (P= 0.001) and
U87-BevR (P= 0.002) xenografts (Supplementary Figure S3b).
Mechanisms of TAM recruitment after bevacizumab treatment
We then investigated potential mechanisms of these findings of
increased TAMs after bevacizumab treatment of sensitive and
resistant xenografts from both models. We first performed
monocyte chemotaxis assays using conditioned media (CM) from
U87-BevR and U87-BevS cells to determine whether tumor cells
from resistant versus sensitive xenografts exhibited differential
chemotaxis of recruited monocytes. The chemotactic response of
human THP-1 monocytes to monocyte chemotactic protein-1
(MCP-1/CCL2), an important monocyte-attracting chemokine, was
reduced after pre-treatment with U87-BevR CM versus U87-BevS
CM (P= 0.03) (Supplementary Figure S4). Furthermore, the
chemotactic response of THP-1 monocytes was weaker to U87-
BevR CM than to U87-BevS CM (Po0.0001) (Figure 1d). In contrast,
CM from U87-BevR cells increased the number of bone marrow-
derived murine macrophages relative to CM from U87-BevS cells
(P= 0.04) (Figure 1e). Thus, while the total number of TAMs
increased comparably in sensitive U87-BevS versus resistant U87-
BevR intracranial xenografts after bevacizumab treatment, tumor
cells from the sensitive xenografts achieved this increase through
more monocyte chemotaxis while tumor cells from resistant
xenografts achieved this increase by promoting proliferation of
differentiated macrophages.
Macrophage polarization after bevacizumab resistance
We then determined whether the increased TAMs seen in both
sensitive and resistant xenografts after bevacizumab treatment
were differentially polarized towards the M1 anti-tumoral or M2
protumoral subtype in sensitive versus resistant xenografts. To do
so, we isolated CD11b+ macrophages from intracranial U87-BevR
versus U87-BevS xenografts using fluorescence activated cell
sorting (FACS) followed by quantitative PCR (qPCR) analysis of
expression of three M1 (Nos2 = inducible nitric oxide synthase,
CXCL10 and IL-1β) and three M2 markers (Arginase 1, TGF-β, and
MMP9), from which we derived an M2/M1 ratio of the expression
of the three M2 markers divided by expression of the three M1
markers. Macrophages from U87-BevR xenografts exhibited higher
M2/M1 ratios than macrophages infiltrating U87-BevS xenografts
independent of whether they were treated with IgG or
bevacizumab (Po0.0001), suggesting durable M2 polarization of
the macrophages once the resistant phenotype had been
established (Figure 1f).
Screening for mediators of macrophage changes in bevacizumab
resistance
To investigate mediators of the increased number of macrophages
and M2 polarization in bevacizumab-resistant xenografts, we
performed a microarray analysis comparing U87-BevR to U87-BevS
xenografts and specifically analyzed tumor-secreted cytokines
with known biologic effects on monocytes or macrophages
(Supplementary Table S1; Figure 2a). Of these cytokines, only
MCP-1/CCL2 and macrophage migration inhibitory factor (MIF)
expression changed significantly during the evolution of bevaci-
zumab resistance in U87-BevR (raw Po0.0001), the former
increasing and the latter decreasing. While CCL2 contributes to
macrophage recruitment,17 qPCR (Figure 2b) and western blot
(Figure 2c) of U87-BevR and U87-BevS xenografts revealed CCL2
mRNA (Po0.05) and protein levels to actually decrease in U87-
BevR xenografts, explaining the reduced chemotaxis of monocytes
to U87-BevR CM than to U87-BevS CM (Figure 1c). Thus, CCL2 was
not the source of the increased macrophages we noted in
bevacizumab-resistant xenografts.
We then further investigated the MIF downregulation identified
in the microarray of our bevacizumab-resistant xenografts
because MIF has potential roles in macrophage recruitment and
polarization.18 We confirmed the microarray results, finding
significant reduction in MIF levels in U87-BevR compared to
U87-BevS xenografts at the transcriptional (Po0.05; Figure 2b)
and protein (Figure 2c) levels. Similarly, tumoral MIF in patient-
derived SF7300 bevacizumab-responsive xenografts was higher
than in patient-derived SF7796 bevacizumab-resistant xenografts
(Supplementary Figure S5). We then corroborated these findings
from both of our xenograft models of bevacizumab resistance in
patient specimens. MIF expression in bevacizumab-resistant
glioblastoma patient specimens (n= 4; two treated with mono-
therapy and two with bevacizumab plus another agent) was lower
than in bevacizumab-naive patient glioblastomas (n= 4)
(Figure 2d).
MIF depletion drives features of bevacizumab-resistant
glioblastoma
To determine whether the M2 polarization noted in bevacizumab-
resistant xenografts reflected altered factor(s) secreted by tumor
cells, we performed bone marrow-derived macrophage polariza-
tion assays. First, murine macrophages were incubated with
recombinant cytokines or tumor cell CM. We then assessed M1 vs
M2 polarization by using qPCR to determine expression of the
three M1 and three M2 markers listed above to calculate M2/M1
ratios. CM from cultured U87-BevR cells yielded more M2-
differentiated macrophages compared to CM from U87-BevS cells
(Po0.0001; Figure 3a). Recombinant MIF at 0.2 and 0.8 μg/ml
converted macrophages to an M1 phenotype in a dose-
dependent manner (Po0.0001; Figure 3a). Thus, the loss of MIF
expression in U87-BevR xenografts proved to be a possible source
of the differential effects of the CM from U87-BevR versus U87-
BevS cells on murine macrophages.
To confirm that the M1 and M2 polarization induced by MIF and
U87-BevR CM, respectively, corresponded to the expected func-
tional differences between these two macrophage subtypes, we
performed macrophage phagocytosis assays on THP-1 human
monocytes differentiated into macrophages and treated with
recombinant MIF or CM from U87-BevR or U87-BevS cells.
Recombinant MIF reduced phagocytosis of these macrophages
(P= 0.005), while U87-BevR CM increased their phagocytosis
relative to U87-BevS CM (P= 0.01; Figure 3b; Supplementary
Figure S6). This finding was consistent with the description of M2
macrophages as more phagocytic than M1 macrophages.19,20
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Next, we performed a sequential conditioned media experiment
to investigate the reciprocal impact of these macrophage changes
induced by U87-BevR versus U87-BevS CM on cultured glioma cells
(Figure 3c). CM from U87-BevR or U87-BevS cells was transferred to
macrophages derived from THP-1 monocytes, followed by
collecting the macrophage CM and applying it to U87-MG cells,
the parental cell line from which U87-BevR and U87-BevS were
derived. The media from macrophages exposed to U87-BevR CM
caused more proliferation (Po0.0001; Figure 3c) but no change in
cell motility (P= 0.6; Supplementary Figure S7) of U87-MG cells
than the media from macrophages exposed to U87-BevS CM
(Po0.0001) (Figure 3c). Thus, the M2 macrophage polarization
induced by U87-BevR cells promoted the tumor cell proliferation
that is part of the aggressive bevacizumab-resistant phenotype.4
We then determined whether the loss of tumor-secreted MIF
induced by anti-angiogenic therapy played a role in the increased
number of macrophages and M2 polarization characterizing the
resistant phenotype in vivo. We therefore engineered U87-MG
cells to express control sequence-targeting shRNA (U87/shCTL) or
each of two different sequences of MIF-targeted shRNAs
(Supplementary Figure S8). U87/shMIF intracranial xenografts
exhibited increased tumor weight (P= 0.04 U87/shMIF1, P= 0.03
U87/shMIF2; Figure 4a; Supplementary Figure S9) and more
CD11b+ cells (P= 0.01; Figure 4b) than U87/shCTL xenografts, with
the CD11b+ cells in U87/shMIF xenografts accumulating at the
tumor edge (Figure 4b). Compared to macrophages in U87/shCTL
xenografts, macrophages in U87/shMIF xenografts had higher M2/
M1 ratios derived from qPCR of the same three M1 and three M2
genes analyzed in Figure 1f (Po0.0001; Figure 4c). A larger
proportion of the C11b+ TAMs in U87/shMIF xenografts expressed
proliferation marker Ki67 by FACS compared to macrophages in
U87/shCTL xenografts (Po0.05) (Figure 4d). These findings
suggest that MIF knockdown increased the number of pro-
tumoral macrophages by promoting their M2 polarization and
proliferation post-differentiation, as occurred in bevacizumab-
resistant xenografts. And, contrary to prior reports in other cell
types,21–26 intracranial U87/shMIF xenografts exhibited a greater
vessel density (P= 0.03; Figure 4e; Supplementary Figure S9) than
intracranial U87/shCTL xenografts, while transducing U87 or
LN229 glioma cells with MIF shRNA either increased (U87/shMIF1
P= 0.02 and U87/shMIF2 P= 0.01) or did not change (LN229/
shMIF1 P= 0.8 and LN229/shMIF2 P= 0.4) their invasiveness
(Supplementary Figure S10). These findings suggested that MIF
depletion could promote compensatory angiogenesis during
bevacizumab resistance and could contribute to or at least not
offset the increased invasiveness seen during bevacizumab
resistance.14,15
We then investigated the reciprocal question: the impact of
overexpressing MIF in resistant U87-BevR cells (Supplementary
Figure S11) on tumor growth and TAM polarization. Xenografts
derived from two U87-BevR-derived clones transduced to over-
express MIF exhibited decreased tumor weight (P= 0.03 U87/BevR-
MIF1, P= 0.009 U87/BevR-MIF2) (Figure 5a), decreased TAMs
(P= 0.006; Figure 5b), increased M1/M2 ratio (P= 0.002 U87/BevR-
MIF1, P= 0.01 U87/BevR-MIF2; Figure 5c), and decreased angio-
genesis (P= 0.046 U87/BevR-MIF1 and P= 0.04 U87/BevR-MIF2;
Figure 5d). Thus, MIF restoration reversed some of the features of
tumor growth and the tumor microenvironment seen with
bevacizumab resistance.
Mechanisms of MIF depletion during bevacizumab resistance
Having established the importance of MIF downregulation in
driving M2 macrophage polarization and proliferation in
bevacizumab-resistant glioblastomas, we then characterized the
mechanisms of MIF downregulation in bevacizumab-resistant
glioblastomas. To do so, we investigated the direct interaction
between MIF and bevacizumab, as well as the relationship
between MIF and VEGF, the target of bevacizumab. We used
immunoprecipitation to perform an in vitro protein-protein
binding assay with bevacizumab and recombinant MIF, which
revealed that pure bevacizumab binds recombinant MIF in a dose-
dependent manner (Figure 6a). This direct binding, unlikely to
Figure 2. Decreased MIF expression associated with bevacizumab-resistant glioblastoma. (a) Microarray analysis of U87-BevR relative to U87-
BevS (n= 3/group) was performed to assess tumor-secreted factors known to influence macrophages, with only two changes being
statistically significant (*raw Po0.001): upregulated CCL2 and downgregulated MIF. (b) qPCR revealed reduced CCL2 and MIF transcript
(Po0.05 each), while (c) Immunoblotting revealed reduced CCL2 and MIF protein in U87-BevR xenografts (n= 5) compared to U87-BevS
intracranial xenografts (n= 5). (d) Immuoblotting revealed reduced MIF in bevacizumab-resistant patient glioblastomas (n= 4) compared to
bevacizumab-naive patient glioblastomas (n= 4).
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involve accessory proteins because studies were performed using
pure recombinant proteins free of other molecules, offers one
potential mechanism by which bevacizumab could reduce MIF
levels. To confirm that the bevacizumab-MIF binding identified by
immunoprecipitation was a functional interaction in which
bevacizumab sequestered MIF and reduced its functional effects,
we repeated the macrophage polarization assay from Figure 3a in
the presence of recombinant MIF and/or bevacizumab. Bevacizu-
mab blocked the ability of recombinant MIF to drive M1
polarization as assessed using qPCR to measure the M1/M2 ratio
of the fold change in the three M1 and three M2 markers
described above (Figure 6a).
MIF secretion occurs through a unique mechanism in which MIF
is initially stored in vesicles, and then released through an ATP-
binding cassette transporter ABCA1. MIF secretion can therefore
be regulated at the level of transcription as well as secretion.
Using qPCR, immunoblotting, and ELISA, we showed that VEGF
drives MIF expression through both short-term post-translational
effects and longer-term transcriptional effects in U87-MG and
U251 glioblastoma cells (Figure 6b), offering a mechanism through
which VEGF depletion caused by prolonged bevacizumab
treatment can reduce MIF expression. To determine which VEGF
receptor mediated VEGF-driven MIF expression, U87-MG cells
were treated with VEGF in the presence of blocking antibodies
targeting VEGF receptors-1 and 2 (VEGR-1 and VEGFR-2). Blocking
VEGFR-2 eliminated VEGF-induced MIF expression, while blocking
VEGFR-1 did not alter VEGF-induced MIF expression (Figure 6c;
Supplementary Figs. S12-S13).
Because macrophages localized to the tumor edge in our
intracranial bevacizumab-resistant xenografts, we investigated the
spatial variability in macrophage infiltration and associated factors
in patient specimens. We analyzed VEGF and MIF expression by
absolute quantification qPCR in site-directed biopsies from the
central core, enhancing edge, and FLAIR bright infiltrated white
Figure 3. In cultured cells, MIF promotes M1 polarization, causing macrophages to be less phagocytic and exert a less pro-tumoral effect.
(a) Murine bone marrow-derived macrophage precursors were matured for 5 days and rested for 3 days prior to an 18 hour polarization in
media containing 200 ng/ml and 800 ng/ml MIF, 20 ng/ml IFN-γ (for M1 polarization), 20 ng/ml IL-4 (for M2 polarization), or conditioned media
from U87-BevR or U87-BevS cells (n= 3/group). M1/M2 polarization ratio was assessed by multiplication of the qPCR fold increases in three
different M1 primers divided by the qPCR fold increases in three different M2 primers normalized to results when incubating with media
alone. Recombinant MIF drove M1 polarization in a dose-dependent manner (Po0.0001), while, unlike media from U87-BevS cells, media from
U87-BevR cells drove an M2 macrophage polarization (Po0.0001). (b) The phagocytic activity of THP-1 monocyte-derived macrophages
without stimulation, cultured with cytokines (recombinant MIF, IFN-γ, and IL-4), or cultured with conditioned media (CM) was assessed via
uptake of fluorescent heat-killed E. coli with subsequent measurement of the proportion of fluorescent cells (n= 6/group). M1 polarized
macrophages were less phagocytic whereas M2 polarized macrophages were more phagocytic relative to unstimulated control macrophages.
Macrophages treated with 800 ng/ml MIF were less phagocytic relative to control (P= 0.005). Macrophages treated with CM from U87-BevR
cells were more phagocytic than macrophages treated with CM from U87-BevS (P= 0.01) (example images shown to the right). (c) Sequential
conditioned media (SCM) experiments were performed as illustrated to the left. Briefly, media from U87-BevR or U87-BevS cells was applied to
THP-1-derived macrophages, and the media was then taken from those macrophages and applied to U87 cells, with numbers of U87 cells
counted 48 h later (n= 24/group). U87-BevR-derived macrophage conditioned media (U87-BevR MCM) stimulated a significantly greater
expansion of U87 cells than U87-BevS-derived macrophage conditioned media (U87-BevS MCM) (Po0.0001), with U87-BevR MCM and U87-
BevS MCM stimulating more (P= 0.005) and less (P= 0.003) U87 expansion than control media, respectively.
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matter outside of enhancement from patient bevacizumab-naive
glioblastomas, obtained as illustrated in Supplementary Figure S1.
VEGF and MIF expression peaked together at the enhancing edge
relative to the central core or infiltrated white matter (n= 4 cases;
P= 0.01–0.02; Figure 6d), consistent with the VEGF regulation of
MIF expression that we noted in cultured U87-MG cells. Site-
directed biopsies from the same locations in bevacizumab-
resistant glioblastomas (n= 3; same cases as Figure 1b) revealed
that VEGF mRNA once again elevated at the enhancing edge
(P= 0.03). This finding is expected in bevacizumab-treated tumors
because bevacizumab targets VEGF protein; therefore, VEGF
regional transcriptional patterns should be preserved in
bevacizumab-resistant glioblastomas. However, given the binding
efficiency of bevacizumab to VEGF (Figure 6a), nearly all of the
VEGF protein should be neutralized by bevacizumab in a treated
tumor.27 In contrast to the preserved regional variation in VEGF
expression, MIF mRNA was suppressed in all regions of
bevacizumab-resistant glioblastomas, including at the enhancing
edge where it normally peaked (P= 0.02 vs bevacizumab-naive
enhancing edge; Figure 6d). This suggests that bevacizumab
neutralization of VEGF eliminating VEGF-induced MIF transcription,
one of two mechanisms of bevacizumab-induced MIF depletion
we identified, was a significant mechanism in bevacizumab-
resistant patient tumors. We then isolated CD11b+ macrophages
through column purification of site directed biopsies from
bevacizumab-naive and bevacizumab-resistant glioblastomas.
We performed absolute quantification qPCR to calculate regional
M2/M1 ratios from the three M1 and three M2 markers described
above. We found that bevacizumab-naive and resistant glioblas-
tomas both had M2 macrophages predominating relative to M1
in the central core and infiltrated white matter. Within the
enhancing edge, however, where MIF expression was lost during
bevacizumab resistance, bevacizumab-resistant glioblastomas
were enriched for M2 macrophages, while bevacizumab-naive
glioblastomas were enriched for M1 macrophages (Po0.0001
bevacizumab-naive versus bevacizumab-resistant M2/M1 at
enhancing edge; Figure 6d).
DISCUSSION
We found MIF depletion during anti-angiogenic therapy to cause
both the increased TAMs and increased M2 polarization of these
Figure 4. MIF reduction increases tumor-associated macrophages and drives M2 polarization in vivo. Intracranial xenografts established
from U87 glioma cells transduced with two different MIF-targeted shRNA sequences versus control-targeted shRNA sequences exhibited
(n= 3/group) (a) larger tumor weights (P= 0.04 U87/shMIF1 and P= 0.03 U87/shMIF2); (b) more TAMs (red) (P= 0.01), with the TAMs
preferentially localizing to the tumor (green) periphery; (c) increased M2 TAM polarization based on elevated M2/M1 ratios (Po0.0001) in
CD11b+ FACS-sorted TAMs analyzed by qPCR; (d) more proliferative TAMs based on FACS revealing a larger percentage of CD11b+ TAMs to be
positive for the proliferation marker Ki67 (Po0.05); and (e) more vessel density based on CD31 vessel staining (P= 0.03). Scale bars, 50 μm.
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macrophages that bevacizumab-resistant glioblastomas exhibit.
Our findings suggest a sequence in which bevacizumab reduces
tumor cell MIF expression, which typically occurs at the edge of
bevacizumab-naive glioblastoma, early during treatment. This
reduced MIF leads to increased proliferation of TAMs at the tumor
edge while the treatment is still effective, which we found in our
two xenograft models of bevacizumab sensitivity versus resistance
and also found to be unique to bevacizumab treatment as
compared to other treatments in our patient specimens.
Eventually, the increased macrophages at the tumor edge become
M2 polarized, which is also due to the loss of MIF at this location.
The M2 macrophages at the tumor edge then promote tumor cell
proliferation and the invasive growth that characterizes bevacizu-
mab resistance.
We identified two mechanisms that could explain how VEGF
depletion could trigger MIF depletion, loss of VEGF-induced MIF
transcription and bevacizumab neutralization of MIF. Loss of VEGF-
induced MIF transcription is supported by our site-directed
biopsies from bevacizumab-resistant glioblastomas. The ability of
bevacizumab to bind VEGF, shown by our protein-protein binding
assay, is also supported by protein BLAST analysis, which although
only demonstrating 31% protein homology between MIF and
VEGF, confirmed homology between amino acids 48–76 of MIF
and amino acids 29–51 of VEGF, the latter of which contains
residues implicated in bevacizumab binding.28 While these effects
on MIF would occur commonly and in a relatively short-term upon
initiating bevacizumab treatment, MIF reduction is likely only
severe enough to trigger TAM polarization changes and ensuing
effects on tumor growth in a subset of tumors treated for longer
time. One of the two mechanisms we identified for bevacizumab-
induced MIF depletion could arise with VEGFR2-targeted thera-
pies, as these therapies would not directly deplete MIF the way
that we found bevacizumab could but the effect of these
therapies on tumor cell VEGFR2 could prevent VEGF-induced
MIF secretion based on our data. Future studies are needed to
confirm whether MIF depletion occurs with VEGFR2-targeted
therapy or is unique to VEGF-targeted anti-angiogenic therapy.
We found that the increased TAMs occurring during MIF
reduction was due to increased macrophage proliferation rather
than increased recruitment of circulating monocytes. This
proliferative expansion of macrophages is a signature of type-2
inflammation associated with CD4+ T helper 2 (TH2) cells and M2
macrophages.29 Further work is needed to clarify if bevacizumab
resistance increases intratumoral TH2 cells.
Additionally, we found that the increased TAMs associated with
anti-angiogenic therapy resistance occurred primarily at the
enhancing tumor edge. Recent studies have found that micro-
environmental variations affect the spatial distribution and density
of macrophage subtypes in inflammatory conditions.30,31 Similarly,
spatial variability in TAM polarization correlates with hypoxia in
Figure 5. MIF overexpression in bevacizumab-resistant cells decreases tumor-associated macrophages and drives M1 polarization in vivo.
Intracranial xenografts established from U87-BevR glioma cells transduced to overexpress MIF in two different clones relative to U87-BevR cells
transduced with empty vector (EV) exhibited (n= 3/group) (a) decreased tumor weight (P= 0.03 U87-BevR/MIF1 and P= 0.009 U87-BevR/MIF2);
(b) increased CD11b+ TAMs (P= 0.006 for both U87-BevR/MIF1 and U87-BevR/MIF2 compared to U87-BevR/EV) (CD11b+ cells red, GFP+ tumor
cells green, DAPI rendering nuclei blue); (c) increased M1/M2 ratio (P= 0.002 U87/BevR-MIF1, P= 0.01 U87/BevR-MIF2); and (d) decreased
vascularity (P= 0.046 U87-BevR/MIF1 and P= 0.04 U87-BevR/MIF2). Scale bars, 50 μm.
MIF downregulation drives anti-angiogenic therapy resistance
BA Castro et al
3755
Oncogene (2017) 3749 – 3759
non-brain tumors in mice.32 Our findings of regional variation in
MIF levels, with MIF peaking at the enhancing edge of patient
bevacizumab-naive glioblastomas, would suggest MIF as an
important source of regional variation of macrophage polarization.
Increased MIF expression at the enhancing edge of glioblastoma
could create a regional M1 polarization zone that somewhat
confines tumor cells to the enhancing region, a confinement that
is lost when bevacizumab depletes MIF, thereby softening the
tumor border through M2 polarization and ultimately leading to
invasive resistance.
The ability of tumor-secreted MIF to cause reduced angiogen-
esis, reduced tumor growth, and neutral to reductive effects on
tumor cell invasiveness that we demonstrated, all anti-tumoral
functions lost in bevacizumab-resistant glioblastomas, must be
reconciled with studies showing pro-tumoral MIF effects on tumor
cells such as promoting invasion and proliferation23–26 or on the
microenvironment such as promoting angiogenesis21,22 or escape
from NK cell-mediated cytotoxicity.33 Even our finding that MIF
drives M1 TAM polarization, while consistent with reports in
adipose cells in MIF knockout mice34 and a study correlating
glioblastoma TAM expression of MIF receptor CD74 with M1
polarization,35 must be resolved with reports suggesting that MIF
can drive pro-tumoral M2 macrophage polarization.18,36
There are several potential explanations for these conflicting
findings. First, tumor cell-secreted23–26 versus stromal cell-
secreted18,37,38 MIF could exert different effects on tumor cells
or their microenvironment. Second, the cytokine milieu, which is
affected by tumor type and therapeutic response, might alter MIF
function. Third, there may be a dose-response relationship in
which the collective effect of MIF on tumors is pro-tumoral at both
Figure 6. Dual mechanisms of bevacizumab-induced MIF depletion. (a) Immunoprecipitation revealed that bevacizumab bound MIF, with
bevacizumab binding of VEGF serving as a positive control (upper portion of figure). Bevacizumab blocked the ability of recombinant MIF to
drive M1 polarization in cultured bone marrow cells (lower portion of figure). (b) Treatment of cultured U87 and U251 cells with 100 ng/ml
recombinant VEGF for varying time points up to 48 hours revealed that VEGF increased MIF transcription by qPCR, intracellular protein by
western blot of whole cell lysate, and protein secretion by ELISA (Po0.01), offering a potential mechanism by which bevacizumab could
reduce tumoral MIF. (c) Cultured U87 cells were treated with VEGF in the presence of blocking antibodies targeting VEGF receptors-1 and 2
(VEGR-1 and VEGFR-2). Blocking VEGFR-2 eliminated VEGF-induced MIF expression, while blocking VEGFR-1 had no effect on VEGF-induced
MIF expression. (d) Site-directed biopsies taken from four bevacizumab-naive recurrent glioblastomas revealed increased MIF and VEGF RNA
copies at the enhancing edge relative to the central core and FLAIR bright non-enhancing periphery, as assessed by absolute quantification
qPCR (P= 0.03). In contrast, site-directed biopsies taken from a bevacizumab-resistant recurrent glioblastoma revealed the same regional
pattern in VEGF RNA levels, but loss of the spike in MIF RNA that typically occurs at the enhancing edge (P= 0.02). Absolute quantification
qPCR of column purified CD11b+ cells from bevacizumab-naive versus recurrent glioblastoma revealed elevated M2/M1 ratio at the central
core and infiltrated white matter in both tumor types, but at the enhancing edge the bevacizumab-naive tumor had predominantly M1
macrophages, while the resistant tumor had predominantly M2 macrophages (P= 0.008-0.01).
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extremely low and high levels. Just as VEGF depletion itself has
direct adverse effects due to VEGF’s pro-angiogenic effects being
balanced by its anti-invasive role,39 suggesting that intermediate
tumoral VEGF levels may be optimal, achieving a balance between
MIF’s pro-tumoral versus anti-tumoral functions may require
intermediate tumoral MIF levels. In the case of VEGF blockade,
this would support intermediate dosing strategies.40 Fourth, post-
translational modifications of MIF like glycosylation or N-cysteiny-
lation, driven partly by local tumoral levels of reactive oxygen
species (ROS),41 could shift the pro-tumoral versus anti-tumoral
balance in MIF functions. This would mean that therapies
targeting MIF, which have been investigated preclinically, should
be used with caution and it would be preferable to target a MIF
form that preferentially exerts its pro-tumoral effects, such as the
oxidized MIF currently being targeted in a clinical trial (Clinical-
Trials.Gov; NCT01765790).
Further work is needed to clarify where in the spectrum of other
described mechanisms of resistance to anti-angiogenic therapy
our mechanism falls. These other mechanisms include vessel co-
option42 driven by actin-related protein 2/3 complex (Arp2/3);43
tumor cell invasion driven by c-Met14,44 and β1 integrin;15
hypoxia-driven expression of hyaluronic acid and sulfated
glycosaminoglycans (sGAGs);45 increased angiopoietin-2 expres-
sion by endothelial cells;46 upregulation of tumor cell DLL4-Notch
signaling;47 increased tumor cell expression of VEGFR-2;48
increased tumor cell expression of branched-chain amino acid
transaminase1;49 Tie2-expressing monocytes;5,6,44 evolution of a
mesenchymal phenotype;5,14,50 and increased hypoxia-inducible
protein 2 (HIG2).51 It remains unclear if these multiple mechanisms
occur in parallel or if resistance to anti-angiogenic therapy is
heterogeneous. Clinically, answering this question is challenging
because bevacizumab is typically used in combination with DNA
damaging chemotherapy.
Continued validation of our mechanism would open up novel
therapeutic opportunities. While some have suggested combining
anti-angiogenic therapy with immunomodulatory approaches
such as anticancer vaccines (ClinicalTrials.gov, NCT01814813) or
T-cell targeted approaches,52 our work suggests a role for
combining anti-angiogenic therapy with strategies promoting
M1 macrophage polarization such as antibodies targeting colony-
stimulating factor 1 receptor (CSF1R), which are undergoing
clinical trials.53 Such an approach could prevent the entrenchment
of bevacizumab resistance and improve the clinical efficacy of
VEGF-targeted anti-angiogenic therapy, allowing this modality to
fulfill its tremendous therapeutic promise.
MATERIALS AND METHODS
Cell culture
U87-MG (ATCC HTB-14), U251 (Sigma-Aldrich, Milwaukee, WI, USA), and
LN229 (ATCC CRL2611) human glioblastoma cells and THP1 human
monocytes (ATCC TIB-202) were passaged fewer than six months and
verified by providing companies using short tandem repeat (STR) profiling
and confirmed to be Mycoplasma free. Cells for culture were obtained from
U87-BevR, U87-BevS, SF7300, and SF7796 xenografts generated as
described.14,15 Glioblastoma cells were cultured in DMEM High Glucose/
F-12 50/50% mixture media with 10% FBS and 1% penicillin/streptomycin
at 37 °C. THP1 cells were cultured in RPMI-1640 medium with 10% FBS,
L-glutamine (2 mmol/l), 2-mercaptoethanol (55 μM; Gibco) and 1%
penicillin/streptomycin at 37 °C.
Conditioned media
CM from subconfluent U87-MG or THP-1 cells growing for 48 h was
centrifuged at 400 g for 5 min, and the supernatant was collected and
stored at 20 °C. Sequential conditioned media (SCM) was prepared by
applying U87-BevR/U87-BevS CM to differentiated macrophages; this
media was then collected and applied to U87-BevS cells (n=24 technical
replicates/group).
MIF shRNA and cDNA
Lentiviral clones containing two shRNA sequences against human MIF and
a control sequence (GE Dharmacon), lentivirus packaging plasmid psPAX2,
envelope plasmid VSV-G, and transfection reagent FuGENE6 (Promega)
were used to produce viral particles from HEK293T cells. Lentivirus was
added to U87-MG and LN229 cells in DMEM media supplemented with
10% FBS and polybrene (Santa Cruz Biotechnology) per manufacturer’s
protocol. To overexpress MIF, human MIF cDNA was generated as a PCR
product (primers in Supplementary Table S2) from a plasmid containing
MIF cDNA (Origene) in the pENTR/D-TOPO Cloning Kit (Invitrogen),
sequenced, and cloned into the pLenti6.3/V5-DEST Gateway Vector (Life
Technologies, Carlsbad, CA, USA). Cultured U87-BevR cells were transduced
with empty or MIF-containing vector, from which U87-BevR/EV (empty
vector) along with U87-BevR/MIF1 and U87-BevR/MIF2, two clones over-
expressing MIF relative to U87-BevR, were selected, with resulting cells
GFP+ due to the vector GFP gene.
Microarray analysis
Tumor chunks previously harvested from generational xenografts had
been flash frozen at explantation and stored in liquid nitrogen. Samples
(n=3 technical replicates/group) were retrieved and dissociated using
passage through a 21-gauge sterile syringe and a QiaShredder (Qiagen,
Germantown, ML, USA). Dissociated tissue was processed for RNA using
the RNeasy kit (Qiagen), following manufacturer’s protocol. RNA was tested
for quality (RIN scores48) using the RNA 6000 chip with the Bioanalyzer
(Agilent). RNA was converted to labeled cRNA using the TargetAmp-Nano
Labeling Kit for Illumina Expression BeadChip (EpiCentre), following
manufacturer’s protocol. Labeled cRNA was kept at -20 °C, with chip
hybridization performed by the UCSF Genome Core Facility (GCF).
Bioinformatics
Data (.idat files) from GCF underwent standard QC and processing through
the UCSF Bioinformatics Core, and were deposited in GEO (Accession
number=GSE81465). BLAST protein comparisons were rendered through
http://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE= Proteins.
qPCR
RNA isolated with an RNeasy kit (Qiagen) was reverse-transcribed into
cDNA with Superscript III (Invitrogen). Power Syber Green Master Mix
(Applied Biosystems) was used with primers described in Supplementary
Table S2. Quantitative real-time PCR was performed on an Applied
Biosystems 7900 HT cycler (Supplementary Methods). The product of
expression of three M1 markers (Nos2 = inducible nitric oxide synthase,
CXCL10, and IL-1β) was divided by the product of expression of three M2
markers (Arginase 1, TGF-β, and MMP9) for M1/M2 ratios and inverted for
M2/M1 ratios.
Western blot
Human tissue and cellular preparations were harvested in radio
immunoprecipitation buffer (RIPA) containing 20 mM Tris-HCl (pH 7.5),
150 mM NaCl, 1 mM Na2EDTA, 1% NP-40, 1% sodium deoxycholate, 2.5 mM
sodium pyrophosphate, 1 mM beta-glycorophosphate, 1 mM Na3VO4, 1 μg/ml
leupeptin (RIPA Buffer, 10x, CST#9806, Cell Signaling, Danvers, MA, USA)
and one tablet each of PhosStop and Complete Mini (Roche, Indianapolis,
IN, USA). Insoluble materials were removed by centrifugation at 14 000 r.p.
m. for 20 min at 4 °C. Protein concentration was determined using the
bicinchronic acid (BCA) assay (Pierce Biotechnology, Rockford, IL, USA).
Samples were prepared with 10–30 μg of protein in RIPA buffer with 4 ×
LDS loading buffer (Cat#LP0001, Life Technologies). Samples were
electrophoresed on SDS–PAGE gels, transferred to PVDF membranes,
probed with primary antibodies overnight, then secondary antibodies for 1
h at room temperature (Supplementary Table S3). Membranes were
developed using Clarity Western ECL substrate (Cat#10026385 Rev A, Bio-
Rad) and radiographic film.
Immunoprecipitation
Immunoprecipitation is described in Supplementary Methods.
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Animal studies
Animal experiments were approved by the UCSF IACUC (approval
#AN105170-02). 200 000 cells were implanted intracranially into the right
frontal lobes of athymic mice (3-4 weeks, female) stereotactically. Mice
were treated intraperitoneally with 10 mg/kg IgG control antibody (cat#
I4506, Sigma) or bevacizumab (Genentech, San Francisco, CA, USA) twice
weekly. For U87-BevR vs U87-BevS, we used five technical replicates/group
to give over 90% power to detect 50% more CD11b+ cells with
bevacizumab treatment. Randomization was not used because tumor size
could not be ascertained non-invasively. Treating personnel were blinded
to treatment group by having different personnel prepare solutions and
code treatment groups. For U87/shCTL vs U87/shMIF and U87-BevR/EV vs
U87-BevR/MIF, n=3 technical replicates/group were used to give over 90%
power to detect 75% change in CD11b+ cells. Resulting tumors were (1)
dissociated into single cell suspensions in 10% FBS/1% PFA for flow
cytometry; (2) perfused with PBS followed by 1% PFA, after which brains
were isolated and kept in 4% PFA overnight, sunk in 30% sucrose,
embedded in OCT, and cut on a cryostat for immunostaining; or (3)
homogenized, then lysed into RIPA buffer for western blotting.
Immunofluorescence
Immunofluorescence staining of de-paraffinized tissues used antibodies
described in Supplementary Table S3, followed by DAPI coverslipping
medium (010020, Southern Biotech., Birmingham, AL, USA). Slides were
imaged using the Zeiss AxioObserver described above. Images were
photographed and CD11b+ cells manually counted by two observers
blinded to treatment group.
Bone marrow experiments
Murine bone marrow cells were harvested from the femurs and tibia of
BALB/c mice and cultured for 16 hours in 25 ng/ml M-CSF. Non-adherent
cells, representing macrophage precursors, were matured for 5 days in
RPMI-1640 supplemented with 10% FBS and 25 ng/ml M-CSF and rested
for 3 days in RPMI-1640 supplemented with 10% FBS. Macrophage
polarization was performed by culturing macrophages for 18 more hours
in RPMI-1640 with 5% FBS and 20 ng/ml IFN-γ (for M1 polarization) (315-05,
Peprotech), 20 ng/ml IL-4 (for M2 polarization) (214-14, Peprotech), CM
from U87-BevR or U87-BevS cells, recombinant murine MIF (300-69,
Peprotech) and/or 40 μg/ml bevacizumab (Genentech).
Phagocytosis, monocyte chemotaxis, and matrigel invasion assays
Are described in Supplementary Methods.
Flow cytometry
Live cells were spun, counted, and resuspended in FACS buffer. Cells were
then incubated with a cell viability assay (Cat# L34959 Thermo Fisher
Scientific, Waltham, MA, USA) and blocked with either mouse Fc block
(anti-mouse CD16/32) (Cat# 553141, BD Biosciences, Bedford, MA, USA) or
human Fc block (Cat# 564219, BD Biosciences, Bedford, MA, USA) per
manufacturers’ protocols. Cells were incubated with fluorescent antibodies
(Supplementary Table S3) along with isotype controls, for 30 min at 4 °C in
the dark. Cells were washed and resuspended in FACS buffer. FACS was
performed on BD FACS Aria3. Data were analyzed with BD FlowJo software
(Tree Star Inc., Ashland, OR, USA).
Isolating CD11b+ cells from site-directed biopsies
With UCSF IRB approval (#11-06160), biopsies were performed after
obtaining informed consent utilizing a three-dimensional intraoperative
navigation system for stereotactic sampling of the FLAIR bright infiltrated
margin outside the enhancement, the enhancing edge of the tumor, and
the central tumor core inside the enhancement before tumor resection
commenced (Supplementary Figure 1). Regional biopsy tissues were
dissociated using the gentleMACS dissociator and the human tumor
dissociation kit (Miltenyi Biotec, Auburn, CA, USA). CD11b+ cells were
isolated from the dissociated samples using microbeads (Miltenyi Biotec)
per manufacturer’s protocol. Other human tissue was obtained through
the UCSF Brain Tumor tissue bank, which banked tissue after informed
patient consent.
Statistics
For continuous variables, a Shapiro-Wilk test was used to confirm a normal
distribution and homogeneity of variances was verified, which occurred for
each analyzed variable. A student’s t-test (paired or unpaired depending
on data) was then used to compare the variables. For multiple
comparisons of normally distributed variables with homogeneous
variances, two way ANOVA was used to analyze for main effects and
interactions. Interobserver variability for manual counting of immuno-
fluorescence was assessed using SPSS VARCOMP analysis. P values are two-
tailed and Po0.05 was considered significant. For microarray statistics, see
Supplementary Methods.
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